Scotia Capital Inc. Has $19.50 Million Holdings in Pfizer Inc. (NYSE:PFE)

Scotia Capital Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 769,582 shares of the biopharmaceutical company's stock after selling 24,664 shares during the quarter. Scotia Capital Inc.'s holdings in Pfizer were worth $19,501,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Northern Trust Corp raised its position in shares of Pfizer by 7.7% during the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock valued at $1,548,889,000 after acquiring an additional 4,167,222 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Pfizer by 3.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock worth $1,045,351,000 after purchasing an additional 1,333,740 shares during the period. Invesco Ltd. increased its holdings in Pfizer by 9.6% in the fourth quarter. Invesco Ltd. now owns 29,458,139 shares of the biopharmaceutical company's stock valued at $781,524,000 after purchasing an additional 2,579,455 shares during the last quarter. Pacer Advisors Inc. lifted its stake in Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after buying an additional 17,957,928 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in Pfizer by 22.2% during the first quarter. Federated Hermes Inc. now owns 17,592,709 shares of the biopharmaceutical company's stock worth $445,799,000 after buying an additional 3,201,087 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

NYSE PFE opened at $23.49 on Monday. The firm's 50 day moving average is $24.36 and its 200-day moving average is $24.55. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $133.55 billion, a PE ratio of 17.02, a price-to-earnings-growth ratio of 0.85 and a beta of 0.52. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.32.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. The Goldman Sachs Group upped their price target on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Citigroup increased their target price on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Leerink Partners decreased their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. BMO Capital Markets lowered their price objective on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, Wolfe Research raised their price objective on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.